DE69835823D1 - METHOD FOR THE TREATMENT OF PATIENTS SUFFERING FROM MULTIPLE SCLEROSIS WITH CONSENSUS INTERFERON - Google Patents
METHOD FOR THE TREATMENT OF PATIENTS SUFFERING FROM MULTIPLE SCLEROSIS WITH CONSENSUS INTERFERONInfo
- Publication number
- DE69835823D1 DE69835823D1 DE69835823T DE69835823T DE69835823D1 DE 69835823 D1 DE69835823 D1 DE 69835823D1 DE 69835823 T DE69835823 T DE 69835823T DE 69835823 T DE69835823 T DE 69835823T DE 69835823 D1 DE69835823 D1 DE 69835823D1
- Authority
- DE
- Germany
- Prior art keywords
- multiple sclerosis
- treatment
- patients suffering
- consensus interferon
- patients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
The present invention encompasses methods for preventing and treating multiple sclerosis by administering to patients in need thereof a therapeutically effective amount of IFN-con in combination with IL-1ra.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/911,893 US6013253A (en) | 1997-08-15 | 1997-08-15 | Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist |
US911893 | 1997-08-15 | ||
PCT/US1998/014622 WO1999008702A1 (en) | 1997-08-15 | 1998-07-15 | Methods for treatment of patients afflicted wih multiple sclerosis using consensus interferon |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69835823D1 true DE69835823D1 (en) | 2006-10-19 |
DE69835823T2 DE69835823T2 (en) | 2007-08-09 |
Family
ID=25431058
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69835823T Expired - Lifetime DE69835823T2 (en) | 1997-08-15 | 1998-07-15 | METHOD FOR THE TREATMENT OF PATIENTS SUFFERING FROM MULTIPLE SCLEROSIS WITH CONSENSUS INTERFERON |
Country Status (18)
Country | Link |
---|---|
US (1) | US6013253A (en) |
EP (1) | EP1003546B1 (en) |
JP (1) | JP3813440B2 (en) |
KR (1) | KR100415636B1 (en) |
CN (1) | CN1183963C (en) |
AT (1) | ATE338563T1 (en) |
AU (1) | AU741074B2 (en) |
CA (1) | CA2299361C (en) |
CY (1) | CY1107314T1 (en) |
DE (1) | DE69835823T2 (en) |
DK (1) | DK1003546T3 (en) |
ES (1) | ES2267188T3 (en) |
HK (1) | HK1030157A1 (en) |
HU (1) | HU229045B1 (en) |
IL (2) | IL134345A0 (en) |
PT (1) | PT1003546E (en) |
TW (1) | TW474817B (en) |
WO (1) | WO1999008702A1 (en) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7214658B2 (en) * | 2004-07-06 | 2007-05-08 | Tact Ip, Llc | Method of delivering a TNF antagonist to the brain of a human by perispinal administration without direct intrathecal injection |
US20030007972A1 (en) * | 1999-02-24 | 2003-01-09 | Edward Tobinick | Cytokine antagonists and other biologics for the treatment of bone metastases |
US6471961B1 (en) * | 1999-02-24 | 2002-10-29 | Edward L. Tobinick | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders |
US6982089B2 (en) | 1999-02-24 | 2006-01-03 | Tact Ip, Llc | Cytokine antagonists for neurological and neuropsychiatric disorders |
US20020131954A1 (en) * | 2000-05-02 | 2002-09-19 | Tobinick Edward L. | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders |
US20030027755A1 (en) * | 2000-12-08 | 2003-02-06 | Jian Guan | Compositions and methods for the rescue of white matter |
US7605177B2 (en) | 2001-05-24 | 2009-10-20 | Neuren Pharmaceuticals Limited | Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration |
US7041314B2 (en) | 2001-05-24 | 2006-05-09 | Neuren Pharmaceuticals Ltd. | GPE analogs and peptidominetics |
US7714020B2 (en) | 2001-05-24 | 2010-05-11 | Neuren Pharmaceuticals Limited | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate |
US7230167B2 (en) | 2001-08-31 | 2007-06-12 | Syngenta Participations Ag | Modified Cry3A toxins and nucleic acid sequences coding therefor |
AU2003209755B2 (en) * | 2002-02-06 | 2007-11-22 | Ares Trading S.A. | Tumor necrosis factor combined with interferon in demyelinating diseases |
AU2003284246A1 (en) * | 2002-10-16 | 2004-05-04 | Samuel F. Hunter | Method for treatment of demyelinating central nervous system disease using gm-csf |
TWI272948B (en) | 2003-05-01 | 2007-02-11 | Ares Trading Sa | HSA-free stabilized interferon liquid formulations |
AU2005211362B2 (en) | 2004-02-02 | 2008-03-13 | Ambrx, Inc. | Modified human interferon polypeptides and their uses |
DE102004008168B4 (en) * | 2004-02-19 | 2015-12-10 | Voxeljet Ag | Method and device for applying fluids and use of the device |
JP2007538048A (en) * | 2004-05-17 | 2007-12-27 | アレス トレーディング ソシエテ アノニム | Hydrogel interferon preparation |
US7731948B2 (en) | 2004-06-01 | 2010-06-08 | Ares Trading S.A. | Stabilized interferon liquid formulations |
WO2005117948A1 (en) | 2004-06-01 | 2005-12-15 | Ares Trading S.A. | Method of stabilizing proteins |
TW200633718A (en) * | 2004-12-16 | 2006-10-01 | Applied Research Systems | Treatment of hepatitis c in the asian population |
BG66458B1 (en) | 2005-03-21 | 2014-10-31 | Иван Иванов | Agent for concurrent inhibition of endogenous gamma interferon |
WO2006119170A2 (en) * | 2005-05-02 | 2006-11-09 | Avigen, Inc. | Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease |
LT1917276T (en) | 2005-08-26 | 2018-05-25 | Ares Trading S.A. | Process for the preparation of glycosylated interferon beta |
JP2009507003A (en) * | 2005-09-01 | 2009-02-19 | アレス トレーディング ソシエテ アノニム | Treatment of optic neuritis |
MX2008014971A (en) | 2006-05-24 | 2008-12-05 | Serono Lab | Cladribine regimen for treating multiple sclerosis. |
KR20100099298A (en) * | 2007-12-20 | 2010-09-10 | 메르크 세로노 에스. 에이. | Peg-interferon-beta formulations |
US9359421B2 (en) | 2008-04-08 | 2016-06-07 | Tigo Gmbh | Suppressor of the endogenous interferon-gamma |
BG66517B1 (en) | 2008-04-08 | 2016-02-29 | Tigo Gmbh | Inhibitor of endogenous human interferon - gamma |
WO2013008102A2 (en) | 2011-07-14 | 2013-01-17 | R.E.D. Laboratories N.V../ S.A. | Methods and compositions for evaluating and/or treating chronic immune diseases |
SI3021873T1 (en) | 2013-07-18 | 2018-12-31 | Xalud Therapeutics, Inc. | Composition for the treatment of inflammatory joint disease |
BG67190B1 (en) | 2017-03-29 | 2020-11-16 | Tigo Gmbh | Anti-gama mutant protein against endogenous human gamma interferon |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6936694B1 (en) * | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
US5075222A (en) * | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
CA2068320C (en) * | 1989-11-29 | 2000-10-17 | Robert Hageman | Production of recombinant human interleukin-1 inhibitor |
WO1991017184A1 (en) * | 1990-04-27 | 1991-11-14 | The Upjohn Company | Modified interleukin-1 inhibitors |
US5372808A (en) * | 1990-10-17 | 1994-12-13 | Amgen Inc. | Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect |
WO1992006707A1 (en) * | 1990-10-17 | 1992-04-30 | Amgen Inc. | Methods and compositions for the treatment of cell proliferation disorders |
US5858355A (en) * | 1990-12-20 | 1999-01-12 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | IRAP gene as treatment for arthritis |
SG47099A1 (en) * | 1991-03-15 | 1998-03-20 | Amgen Boulder Inc | Pegylation of polypeptides |
DK0639079T3 (en) * | 1992-04-30 | 2000-06-13 | Amgen Inc | Methods for the treatment of interleukin-1 and tumor necrosis factor-mediated diseases |
CA2141953C (en) * | 1992-09-17 | 2008-04-08 | Benjamin K. Sabados | Pharmaceutical formulations of interleukin-1 inhibitors |
US5780021A (en) * | 1993-03-05 | 1998-07-14 | Georgetown University | Method for treating type 1 diabetes using α-interferon and/or β-i |
WO1994020517A1 (en) * | 1993-03-08 | 1994-09-15 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Gene transfer for treating a connective tissue of a mammalian host |
JP3723206B2 (en) * | 1993-03-19 | 2005-12-07 | バクスイン・エス・アー | A therapeutic composition for use in humans, characterized by combining muramyl peptide and cytokine |
US6326353B1 (en) * | 1993-03-23 | 2001-12-04 | Sequus Pharmaceuticals, Inc. | Enhanced circulation effector composition and method |
FR2706772A1 (en) * | 1993-06-22 | 1994-12-30 | Vacsyn Sa | Prevention and treatment of septic syndrome with an immunosuppressant, in particular cyclosporin. |
DE69534676T2 (en) * | 1994-02-08 | 2006-08-17 | Amgen Inc., Thousand Oaks | Oral administration of chemically modified proteins |
-
1997
- 1997-08-15 US US08/911,893 patent/US6013253A/en not_active Expired - Lifetime
-
1998
- 1998-07-15 ES ES98933344T patent/ES2267188T3/en not_active Expired - Lifetime
- 1998-07-15 AT AT98933344T patent/ATE338563T1/en active
- 1998-07-15 DE DE69835823T patent/DE69835823T2/en not_active Expired - Lifetime
- 1998-07-15 AU AU83006/98A patent/AU741074B2/en not_active Expired
- 1998-07-15 IL IL13434598A patent/IL134345A0/en active IP Right Grant
- 1998-07-15 PT PT98933344T patent/PT1003546E/en unknown
- 1998-07-15 HU HU0002755A patent/HU229045B1/en unknown
- 1998-07-15 JP JP2000509439A patent/JP3813440B2/en not_active Expired - Lifetime
- 1998-07-15 WO PCT/US1998/014622 patent/WO1999008702A1/en active IP Right Grant
- 1998-07-15 CN CNB988081520A patent/CN1183963C/en not_active Expired - Fee Related
- 1998-07-15 EP EP98933344A patent/EP1003546B1/en not_active Expired - Lifetime
- 1998-07-15 CA CA002299361A patent/CA2299361C/en not_active Expired - Fee Related
- 1998-07-15 DK DK98933344T patent/DK1003546T3/en active
- 1998-07-15 KR KR10-2000-7001097A patent/KR100415636B1/en not_active IP Right Cessation
- 1998-07-29 TW TW087112465A patent/TW474817B/en not_active IP Right Cessation
-
2000
- 2000-02-02 IL IL134345A patent/IL134345A/en not_active IP Right Cessation
-
2001
- 2001-02-16 HK HK01101141A patent/HK1030157A1/en not_active IP Right Cessation
-
2006
- 2006-11-27 CY CY20061101704T patent/CY1107314T1/en unknown
Also Published As
Publication number | Publication date |
---|---|
US6013253A (en) | 2000-01-11 |
WO1999008702A1 (en) | 1999-02-25 |
CA2299361A1 (en) | 1999-02-25 |
EP1003546A1 (en) | 2000-05-31 |
CN1183963C (en) | 2005-01-12 |
ATE338563T1 (en) | 2006-09-15 |
EP1003546B1 (en) | 2006-09-06 |
IL134345A (en) | 2011-03-31 |
TW474817B (en) | 2002-02-01 |
KR100415636B1 (en) | 2004-01-24 |
HU229045B1 (en) | 2013-07-29 |
HK1030157A1 (en) | 2001-04-27 |
CY1107314T1 (en) | 2012-11-21 |
ES2267188T3 (en) | 2007-03-01 |
KR20010030563A (en) | 2001-04-16 |
PT1003546E (en) | 2006-12-29 |
DE69835823T2 (en) | 2007-08-09 |
CA2299361C (en) | 2009-09-29 |
JP3813440B2 (en) | 2006-08-23 |
AU8300698A (en) | 1999-03-08 |
HUP0002755A2 (en) | 2000-12-28 |
HUP0002755A3 (en) | 2001-11-28 |
AU741074B2 (en) | 2001-11-22 |
IL134345A0 (en) | 2001-04-30 |
DK1003546T3 (en) | 2006-10-30 |
CN1267225A (en) | 2000-09-20 |
JP2001515047A (en) | 2001-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69835823D1 (en) | METHOD FOR THE TREATMENT OF PATIENTS SUFFERING FROM MULTIPLE SCLEROSIS WITH CONSENSUS INTERFERON | |
ATE209483T1 (en) | TREATMENT OF MULTIPLE SCLERosis | |
ATE219373T1 (en) | MEDICATIONS FOR THE TREATMENT OF AUTOIMMUNE DISEASES USING INTERFERON-TAU | |
DE69616376T2 (en) | Use of tiagabin for the treatment of sleep disorders | |
ATE161192T1 (en) | METHOD FOR TREATING A DISORDER MEDIATED BY LFA-1 | |
DE69428523T2 (en) | METHOD FOR TREATING MENTAL OR MENTAL DISEASES AND MENTAL OR MENTAL DISEASES ASSOCIATED WITH SEASON | |
DE69703689T2 (en) | THERAPEUTIC APPLICATIONS OF BPI PROTEIN PRODUCTS FOR TREATING HUMAN MENINGOCOCCÄMIA | |
DE69535264D1 (en) | METHOD FOR THE TREATMENT OF DIABETES BY KGF | |
IL161889A0 (en) | Method for treating diseases with omega interferon | |
DE69625682D1 (en) | METHOD FOR TREATING IGNITIONS AND COMPOSITIONS THEREFOR | |
ATE453402T1 (en) | USE OF SERP-1 IN COMBINATION WITH AN IMMUNOSUPPRESSOR TO TREAT ARTHRITIS | |
DE69837322D1 (en) | METHOD FOR THE THERAPEUTIC ADMINISTRATION OF ANTI-CD40L MEDIUM | |
BR9809678A (en) | Triptolyte derivatives useful in the treatment of autoimmune diseases | |
ATE281841T1 (en) | METHOD FOR PRODUCING MIKANIA EXTRACTS CONTAINING MIKANOLIDES AND DIHYDROMICANOLIDES AND USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | |
ATE271879T1 (en) | METHOD FOR TREATING AUTOIMMUNE DISEASES USING TYPE 1 INTERFERONS | |
DE69619187D1 (en) | METHOD FOR TREATING ENGINE DEFICITES | |
DE60144493D1 (en) | METHOD FOR THE DETERMINATION AND TREATMENT OF TUBEROUS SCLEROSIS COMPLEX ASSOCIATED DISEASES | |
DE69623316T2 (en) | CTLA-8 IN COMBINATION WITH G-CSF OR WITH G-CSF AND IL-6, AND USE OF CTLA-8 FOR TREATING INFECTION | |
ATE249832T1 (en) | USE OF OLANZAPINE OR A SALT IN THE MANUFACTURE OF A MEDICATION FOR THE TREATMENT OF AUTISM AND MENTAL RETARDATION | |
ATE295731T1 (en) | OLNZAPINE FOR THE TREATMENT OF DRUG ABUSE | |
DE69307702D1 (en) | USE OF (E) - 2 - (P -FLUOROPHENETHYL) - 3 - FLUOROALLYLAMINE FOR TREATING ALZHEIMER'S DISEASE | |
ATE229343T1 (en) | COMBINATION OF TEMOZOLOMIDE AND ALPHA INTERFERON FOR THE TREATMENT OF ADVANCED CANCER | |
ATE275414T1 (en) | METHOD FOR TREATING ENDANGESTITAL DISEASES BY USING CHOLERATOXIN SUBUNIT B | |
DE69430807D1 (en) | METHOD FOR TREATING LIVER DISEASES AND SIMILAR INDICATIONS WITH VASODILATING ACTIVE SUBSTANCES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |